tx 3301 has been researched along with Recrudescence in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 4 (80.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hoover, PL; Mold, JW | 1 |
| Haberl, R | 1 |
| Annemans, L; Dresse, A; Kurz, X | 1 |
| Kipp, A | 1 |
5 other study(ies) available for tx 3301 and Recrudescence
| Article | Year |
|---|---|
Does Aggrenox (aspirin/dipyridamole) reduce the risk of recurrent stroke to a greater degree than aspirin alone?
Topics: Aspirin; Aspirin, Dipyridamole Drug Combination; Dipyridamole; Drug Combinations; Humans; Platelet Aggregation Inhibitors; Recurrence; Stroke | 2008 |
[PRoFESS study presented. Change in secondary prevention].
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Aspirin, Dipyridamole Drug Combination; Benzimidazoles; Benzoates; Clopidogrel; Controlled Clinical Trials as Topic; Dipyridamole; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Humans; Ischemic Attack, Transient; Multicenter Studies as Topic; Placebos; Platelet Aggregation Inhibitors; Recurrence; Risk; Stroke; Telmisartan; Ticlopidine; Time Factors | 2003 |
[ASS and dipyridamole combination. A decisive contribution to secondary prevention after stroke].
Topics: Aspirin; Aspirin, Dipyridamole Drug Combination; Clinical Trials as Topic; Delayed-Action Preparations; Dipyridamole; Drug Combinations; Fibrinolytic Agents; Humans; Platelet Aggregation Inhibitors; Recurrence; Stroke | 2003 |
[An acetylsalicylic acid-dypiridamole combination (Asasantine) in the prevention of the recurrence of cerebrovascular accidents (a cost-effectiveness analysis)].
Topics: Aspirin; Aspirin, Dipyridamole Drug Combination; Belgium; Cerebrovascular Disorders; Cost-Benefit Analysis; Costs and Cost Analysis; Delayed-Action Preparations; Dipyridamole; Disease-Free Survival; Drug Combinations; Drug Costs; Economics, Pharmaceutical; Follow-Up Studies; Humans; Markov Chains; Placebos; Platelet Aggregation Inhibitors; Recurrence; Sensitivity and Specificity; Social Security | 1998 |
Second stroke.
Topics: Aspirin; Aspirin, Dipyridamole Drug Combination; Chemoprevention; Dipyridamole; Drug Approval; Drug Combinations; Humans; Platelet Aggregation Inhibitors; Recurrence; Stroke; United States; United States Food and Drug Administration | 2000 |